Zumutor Biologics, a next generation Tumor-Directed IO therapeutics announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its novel monoclonal antibody ZM008 developed to treat various locally advanced or metastatic solid tumours.
